Article thumbnail

A prospective analysis of chemotherapy following surgical resection of clinical stage I-II small-cell lung cancer

By S. Davis, L. Crino, M. Tonato, S. Darwish, P. G. Pelicci and F. Grignani


Thirty-seven (37) consecutive patients with clinical Stage I (T1-2NO, Mo), and Stage II (T1-2N1 Mo) central small-cell lung cancer (SCLC) underwent complete surgical resection of the primary tumor. Ten patients were subsequently pathologically Stage I, 14 patients were Stage II, and 8 were Stage III (T3;N2). The pathologically Stage I, II, and III patients were then treated with chemotherapy consisting of cyclophosphamide (1 g/m2), doxorubicin (50 mg/m2), and vincristine 2 mg (CAV) every 3 weeks for six courses followed by prophylactic cranial irradiation (2000 cGy in 10 fractions). Median survival in Stage I patients is 162 weeks and calculated 5-year survival is 50%; for Stage II patients, median survival is 86 weeks and calculated 5-year survival is 35%. T3;N2 patients have a median survival of 63 weeks; calculated 5-year survival is 21%. Our data suggest surgery plus adjuvant chemotherapy and cranial irradiation results in long-term survival in early central SCLC. These data support the need for randomized surgical trials in Stage I, II, and III central SCLC

Topics: Neoplasm Staging, Humans, Vincristine, Aged, Pilot Projects, Cyclophosphamide, Doxorubicin, Carcinoma, Small Cell, Prospective Studies, Lung Neoplasms, Adult, Antineoplastic Combined Chemotherapy Protocols, Middle Aged, Chemotherapy, Adjuvant, Female, Male, Survival Analysis, Settore MED/04 - Patologia Generale
Publisher: 'Ovid Technologies (Wolters Kluwer Health)'
Year: 1993
DOI identifier: 10.1097/00000421-199304000-00001
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.